Literature DB >> 33947103

Piceatannol-Loaded Bilosome-Stabilized Zein Protein Exhibits Enhanced Cytostatic and Apoptotic Activities in Lung Cancer Cells.

Nabil A Alhakamy1,2,3, Giuseppe Caruso4, Mohammed W Al-Rabia5, Shaimaa M Badr-Eldin1,6, Hibah M Aldawsari1,3, Hani Z Asfour5, Samah Alshehri7, Sami H Alzaharani8, Meshari M Alhamdan8, Waleed Y Rizg1,2,3, Ahmed N Allam9.   

Abstract

Piceatannol (PIC) is a naturally occurring polyphenolic stilbene, and it has pleiotropic pharmacological properties. Moreover, PIC has cytotoxic actions among various cancer cells. In this work, preparations of PIC-loaded bilosome-zein (PIC-BZ) were designed, formulated, and characterized, and the optimized PIC-BZ cytotoxic activities, measured as half maximal inhibitory concentration (IC50), against lung cancer cell line was investigated. Box-Behnken design was utilized in order to examine the effect of preparation factors on drug entrapment and particle size. PIC-BZ showed a spherical shape after optimization, and its particle size was determined as 157.45 ± 1.62 nm. Moreover, the efficiency of drug entrapment was found as 93.14 ± 2.15%. The cytotoxic activity evaluation revealed that the adjusted formulation, which is PIC-BZ formula, showed a substantially smaller IC50 versus A549 cells. Cell cycle analysis showed accumulation of cells in the G2-M phase. Moreover, it showed in the sub-G1 phase, a rise of cell fraction suggestion apoptotic improving activity. Increased early and late phases of apoptosis were demonstrated by staining of cells with annexin V. Furthermore, the cellular caspase-3 protein expression was significantly raised by PIC-BZ. In addition, the wound healing experiment confirmed the results. To conclude, compared to pure PIC, PIC-BZ demonstrated a higher cell death-inducing activity against A549 cells.

Entities:  

Keywords:  A549cells; apoptosis; bilosomes; piceatannol; zein

Year:  2021        PMID: 33947103     DOI: 10.3390/pharmaceutics13050638

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  62 in total

Review 1.  Natural products for treating colorectal cancer: A mechanistic review.

Authors:  Xuan-Mei Huang; Zhi-Jie Yang; Qing Xie; Zi-Kang Zhang; Hua Zhang; Jun-Ying Ma
Journal:  Biomed Pharmacother       Date:  2019-06-22       Impact factor: 6.529

2.  PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma.

Authors:  Fathia Zaki El Sharkawi; Shaimaa Mohammed Ewais; Rania Hassan Fahmy; Laila Ahmed Rashed
Journal:  J Drug Target       Date:  2017-02-16       Impact factor: 5.121

3.  Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting.

Authors:  L F Lai; H X Guo
Journal:  Int J Pharm       Date:  2010-11-19       Impact factor: 5.875

Review 4.  Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents.

Authors:  Célia Faustino; Cláudia Serafim; Patrícia Rijo; Catarina Pinto Reis
Journal:  Expert Opin Drug Deliv       Date:  2016-05-02       Impact factor: 6.648

5.  Piceatannol promotes apoptosis via up-regulation of microRNA-129 expression in colorectal cancer cell lines.

Authors:  Haogang Zhang; Ruichun Jia; Chunjing Wang; Tianming Hu; Fujing Wang
Journal:  Biochem Biophys Res Commun       Date:  2014-09-08       Impact factor: 3.575

Review 6.  Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery.

Authors:  Chiranjeevi Peetla; Andrew Stine; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

7.  Thymoquinone-induced antitumor and apoptosis in human lung adenocarcinoma cells.

Authors:  Saeed Samarghandian; Mohsen Azimi-Nezhad; Tahereh Farkhondeh
Journal:  J Cell Physiol       Date:  2018-11-01       Impact factor: 6.384

8.  Antiproliferative and anti-invasive effect of piceatannol, a polyphenol present in grapes and wine, against hepatoma AH109A cells.

Authors:  Yuichiro Kita; Yutaka Miura; Kazumi Yagasaki
Journal:  J Biomed Biotechnol       Date:  2012-02-08

9.  Intranasal Niosomal In Situ Gel as a Promising Approach for Enhancing Flibanserin Bioavailability and Brain Delivery: In Vitro Optimization and Ex Vivo/In Vivo Evaluation.

Authors:  Usama A Fahmy; Shaimaa M Badr-Eldin; Osama A A Ahmed; Hibah M Aldawsari; Singkome Tima; Hani Z Asfour; Mohammed W Al-Rabia; Aya A Negm; Muhammad H Sultan; Osama A A Madkhali; Nabil A Alhakamy
Journal:  Pharmaceutics       Date:  2020-05-27       Impact factor: 6.321

10.  Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates.

Authors:  Shaimaa M Badr-Eldin; Nabil A Alhakamy; Usama A Fahmy; Osama A A Ahmed; Hani Z Asfour; Abdulhamid A Althagafi; Hibah M Aldawsari; Waleed Y Rizg; Wael A Mahdi; Adel F Alghaith; Sultan Alshehri; Filippo Caraci; Giuseppe Caruso
Journal:  Front Pharmacol       Date:  2021-02-03       Impact factor: 5.810

View more
  3 in total

1.  Piceatannol SNEDDS Attenuates Estradiol-Induced Endometrial Hyperplasia in Rats by Modulation of NF-κB and Nrf2/HO-1 Axes.

Authors:  Lenah S Binmahfouz; Basma G Eid; Amina M Bagher; Rasheed A Shaik; Najlaa S Binmahfouz; Ashraf B Abdel-Naim
Journal:  Nutrients       Date:  2022-04-30       Impact factor: 6.706

2.  Development and evaluation of luteolin loaded pegylated bilosome: optimization, in vitro characterization, and cytotoxicity study.

Authors:  Ameeduzzafar Zafar; Nabil K Alruwaili; Syed Sarim Imam; Omar Awad Alsaidan; Mohd Yasir; Mohammed M Ghoneim; Sultan Alshehri; Md Khalid Anwer; Alanood S Almurshedi; Abdullah S Alanazi
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

3.  Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells.

Authors:  Nabil A Alhakamy; Shaimaa M Badr-Eldin; Waleed S Alharbi; Mohamed A Alfaleh; Omar D Al-Hejaili; Hibah M Aldawsari; Basma G Eid; Rana Bakhaidar; Filippo Drago; Filippo Caraci; Giuseppe Caruso
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.